Is MindMed the Future of Medicine?

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF) has been on an absolute tear of late. Due to its groundbreaking work in the psychedelic field, the company’s stock has gained more than 200% in the last 2 months!

Co-founder and Co-CEO JR Rahn is a former Silicon Valley tech executive who partnered with drug development veteran Stephen Hurst to form MindMed in 2019. JR has helped create a leading clinical drug development team with vast experience in psychedelics.

Recently I had the chance to meet with him and discuss the latest positive regulatory feedback. He also shared why he feels MindMed has the greatest toolset to capitalize on the next generation of psychedelic-inspired medicines…

For the full interview and my latest stock recommendations and analysis, sign up for the James West Letter here.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.